ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Humanis Saglık Anonim Sirketi and Knoa Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Humanis Saglık Anonim SirketiKnoa Pharma
studies on the registry4273
open to participants now00
phase 3 studies under way00
reach primary completion within a year00
programswith a study of their own in two years182

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHumanis Saglık Anonim SirketiKnoa Pharma
Phase 1

Humanis Saglık Anonim Sirketi: 18 of its 18 programs at phase 1

  1. Trijardy® XR Tabletsphase 1
  2. bempedoic acidphase 1
  3. Empagliflozin/Linagliptinphase 1
  4. selexipagphase 1
  5. Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)phase 1

and 13 more — sign in to see them all

100%

Knoa Pharma: 1 of its 2 programs at phase 1

  1. Magnesium Chloridephase 1
50%
Phase 200%00%
Phase 300%00%
Approved, new studies00%

Knoa Pharma: 1 of its 2 programs at approved, new studies

  1. nalmefeneapproved, new study
50%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Humanis Saglık Anonim Sirketi0 readouts · 0 phase 3············
Knoa Pharma0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Humanis Saglık Anonim Sirketi

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Knoa Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionHumanis Saglık Anonim SirketiKnoa Pharma
Heart Failureboth · compare here

Knoa Pharma in Heart Failure: 1 program

  1. Magnesium Chloridephase 1

Their studies: Knoa Pharma’s studies of Heart Failure in search

Coronary Artery Diseaseboth · compare here

Humanis Saglık Anonim Sirketi in Coronary Artery Disease: 1 program

  1. bempedoic acidphase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Coronary Artery Disease in search

Knoa Pharma in Coronary Artery Disease: 1 program

  1. Magnesium Chloridephase 1

Their studies: Knoa Pharma’s studies of Coronary Artery Disease in search

Renal Insufficiencyboth · compare here

Humanis Saglık Anonim Sirketi in Renal Insufficiency: 1 program

  1. ertugliflozinphase 1

Their studies: Humanis Saglık Anonim Sirketi’s studies of Renal Insufficiency in search

Knoa Pharma in Renal Insufficiency: 1 program

  1. nalmefeneapproved, new study

Their studies: Knoa Pharma’s studies of Renal Insufficiency in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Humanis Saglık Anonim Sirketi 9 of 18 · Knoa Pharma 1 of 2 programs (10 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.